Skip to main content

Table 2 Univariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival

From: Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma

Parameters   Hazard ratio (95% C.I.) P-value
LINE-1 methylation status    0.017
Q4 (n = 43) Reference  
Q3 (n = 43) 1.575 (0.561–4.602) 0.320
Q2 (n = 43) 3.369 (1.328–8.551) 0.011
Q1 (n = 43) 3.400 (1.349–8.570) 0.009
LINE-1 methylation status Q3, Q4 (n = 86)   
Q1, Q2 (n = 86) 2.643 (1.443–4.482) 0.002
pTNM staging    0.145
I (n = 43) Reference  
II (n = 38) 1.636 (0.739–3.622) 0.224
III (n = 30) 0.543 (0.173–1.709) 0.297
IV (n = 61) 1.602 (0.768–3.342) 0.209
T staging    0.044
pT1 (n = 48) Reference  
pT2a (n = 38) 1.809 (0.866–3.777) 0.114
pT2b (n = 14) 2.344 (0.929–5.913) 0.071
pT3 (n = 47) 0.941 (0.420–2.107) 0.883
pT4 (n = 25) 0.433 (0.123–1.524) 0.192
N staging pN0 (n = 133)   
pN1 (n = 39) 2.328 (1.304–4.157) 0.004
M staging pM0 (n = 161)   
pM1 (n = 11) 1.482 (0.533–4.118) 0.451
Gross type    0.076
Mass forming (n = 141) Reference  
Periductal infiltrative (n = 8) 0 0.964
Intraductal growth (n = 18) 0.134 (0.018–0.971) 0.047
Mixed (n = 5) 2.672 (0.827–8.638) 0.101
Lymphatic emboli Absent (n = 102)   
Present (n = 70) 2.519 (1.429–4.438) 0.001
Vascular invasion Absent (n = 95)   
Present (n = 77) 1.111 (0.634–1.945) 0.714
Perineural invasion Absent (n = 118)   
Present (n = 54) 0.386 (0.181–0.822) 0.014
Tumor border Expanding (n = 32)   
Infiltrative (n = 140) 2.133 (0.846–5.375) 0.108
Tumor differentiation    0.083
Well (n = 23) Reference  
Moderate (n = 94) 9.405 (1.283–68.943) 0.027
Poor (n = 55) 9.671 (1.290–72.518) 0.027
Chemotherapy and/or radiotherapy No (n = 120)   
Yes (n = 52) 0.979 (0.534–1.792) 0.944